Murwere Wokutanga Akatorwa Kurapa Osteoporosis

A BATA FreeRelease 5 | eTurboNews | eTN
Avatar of Linda Hohnholz
rakanyorwa Linda Hohnholz

Transcenta Holding Limited yakazivisa kubudirira kwedosing yemurwere wekutanga muChina Phase I Chidzidzo cheTST002 chekurapa osteoporosis.

Iyi Phase I kliniki yekuedza ndeye randomized uye kaviri-mapofu, placebo-inodzorwa, imwe-inokwira-dose, yakawanda-center study yakagadzirirwa kuongorora kuchengetedzwa, kushivirira, uye pharmacokinetics profile yeTST002 sekurapa kune varwere vane osteoporosis.

TST002 (Blosozumab) ndeyevanhu anti-sclerostin monoclonal antibody semumiriri wezvinodhaka kune osteoporosis uye zvimwe zvirwere zvekurasikirwa kwemapfupa. Iine maitiro maviri ane zvese zviri zviviri anabolic uye anti-resorptive mhedzisiro, iyo inosimudzira kuumbwa kwemapfupa uye inhibits kunyura kwebhonzo, zvichikonzera kukurumidza kuwedzera kwefupa remamineral density uye simba rebhonzo. Kuvharisa sclerostin chiitiko mumunhu akabatwa ne-anti-sclerostin antibody kana neinongoitika genetic deletion kwakaratidzwa senzira inoshanda mukuwedzera bone mineral density (BMD) uye kuderedza kutsemuka kwemapfupa. Parizvino hakuna kubvumidzwa kweanti-sclerostin antibody therapy muChina zvakadaro kunyangwe Romosozumab yekuAmgen yakabvumidzwa muUnited States, Europe neJapan.

Transcenta in-licensed Blosozumab (TST002) kubva kuEli Lilly and Company (“Eli Lilly”) yekusimudzira nekutengeserana muGreater China muna 2019. Eli Lilly akapedza chikamu chechipiri chekiriniki yeBlosozumab muUnited States neJapan uye akawana vimbiso yekuchengetedza. uye efficacy data. Transcenta yakapedza kubudirira kuchinjisa tekinoroji, yakamisa gadziriro yekugadzira munzvimbo yayo yeHangzhou HJB, uye yakapedza kugadzirwa kweGMP kuti ishandiswe mukiriniki pamwe nekuwedzera zvidzidzo zvekiriniki sezvinodiwa neCDE yeTST002 IND application kuChina. IND yeTST002 China yekudzidza yakabviswa kubva kuNMPA musi waSept. 22nd, 2021 yekuongorora TST002 zvakananga kune varwere vane osteopenia.

"TST002 inogona kuve yechipiri anti-sclerostin monoclonal antibody munyika." akadaro Dr. Michael Shi, EVP, Musoro weGlobal R & D uye CMO yeTranscenta. "Tinotarisira kuita ongororo yakadzama kuti tiongorore kuchengetedzeka uye kushivirira kweTST002 uye kuunza nzira dzekurapa dzakanyatsoshanda uye dzakasiyana dzevarwere vekuChina vane osteoporosis."

Parizvino kune vanopfuura 100 miriyoni yevanhu vane dhigirii rakasiyana reosteoporosis muChina uye vanopfuura mamirioni mana vavo vari kurwara neosteoporotic fractures. Nhamba idzi dziri kuwedzera nekuda kwemaitiro emararamiro, kudya uye kuchembera kwevanhu, izvo zvinokonzeresa hutano hwakakosha, hwehupfumi uye hwemagariro mitoro ine chekuita neosteoporosis ine chekuita nekuputsika. Pane zvakakosha zvisingatarisirwi munharaunda yechirwere ichi kunyanya kune varwere vane osteoporosis yakaoma pasinei nekuvapo kwehuwandu hwemaajenti anti-resorptives akadai sebisphosphonate uye anti-RANKL inhibitor uye anabolic agent inotarisa PTH.

Nezvomunyori

Avatar of Linda Hohnholz

Linda Hohnholz

Editor mukuru we eTurboNews yakavakirwa muTN HQ.

Subscribe
Notify of
muenzi
0 Comments
Inline feedbacks
Ona zvese zvataurwa
0
Ndingade pfungwa dzako, ndapota taura.x
Govera ku...